Nitric oxide: Orchestrator of endothelium-dependent responses

Annals of Medicine

Volumn 44, Issue 7, 2012, Pages 694-716

  Félétou, Michel ^a   Köhler, Ralf ^b,c   Vanhoutte, Paul M ^d,e  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e Chonbuk National University   (South Korea)

Author keywords

Atherosclerosis; Cyclo oxygenase; Cytochrome P450 mono oxygenase; Diabetes; Endothelin; Hypertension; Lipoxygenase; Nitric oxide synthase; Oxidative stress; Potassium channels; Soluble epoxide hydrolase; Tetrahydrobiopterin

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ACETYLCHOLINE; ARGININE; CALCIMYCIN; CALCIUM IONOPHORE; CALMODULIN; CYCLIC GMP; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; GUANYLATE CYCLASE; HYDROGEN PEROXIDE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LIPOXYGENASE; N(G),N(G) DIMETHYLARGININE; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; PEROXIDE; POTASSIUM CHANNEL; POTASSIUM ION; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TETRAHYDROBIOPTERIN; UNSPECIFIC MONOOXYGENASE;

ATHEROSCLEROSIS; BIOAVAILABILITY; CALCIUM CELL LEVEL; CALCIUM CONDUCTANCE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HYPERPOLARIZATION; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

BIOLOGICAL FACTORS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84867026935     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.585658     Document Type: Review

References (258)

1. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-1002.
2. Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther. 2009;86:212-15.
3. Vanhoutte PM. Endothelial dysfunction: the fi rst step toward coronary arteriosclerosis. Circulation J. 2009;73: 595-601.
4. Vanhoutte PM, Tang E, Félétou M, Shimokawa H. Endothelial dysfunction and vascular disease. Acta Physiol. 2009; 196:193-222.
5. Tang EHC, Vanhoutte PM. Endothelial dysfunction: a strategic target in the treatment of hypertension? Pfl ugers Arch. 2010;459:995-1004.
6. Vanhoutte PM. Say NO to ET. J Auto Nerv Sys. 2000;81: 271-7.
7. Félétou M, Vanhoutte PM. Endothelium-dependent hyperpolarizations: past beliefs and present facts. Ann Med. 2007;39:495-516.
8. Félétou M, Vanhoutte PM. EDHF: an update. Clin Sci (Lond). 2009;117:139-55.
9. Feletou M, Tang EHC, Vanhoutte PM. Nitric oxide the gatekeeper of endothelial vasomotor control. Front Biosci. 2008;13:4198-217.
10. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
11. Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-6.
12. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: The basis for the proposal that the acid-activable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, editor. Mechanism of vasodilatation. New York, NY: Raven Press; 1988.p. 401-14.
13. Ignarro LJ, Byrns RE, Wood KS. Biochemical and pharmacological properties of EDRF and its similarity to nitric oxide radical. In: Vanhoutte PM, editor. Mechanism of vasodilatation. New York, NY: Raven Press; 1988. p. 427-35.
14. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-6.
15. Moncada S, Palmer RJM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-42.
16. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424.
17. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a camodulin requiring enzyme. Proc Natl Acad Sci U S A. 1990;87:682-86.
18. Bredt TB, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351:714-7.
19. Yui Y, Hattori R, Kosuga K, Eizawa H, Hiki K, Kawai C. Purifi cation of nitric oxide synthase from rat macrophages. J Biol Chem. 1991;266:12544-8.
20. Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem. 1992;267:6370-4.
21. Pollock JS, Fostermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purifi cation and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine endothelial cells. Proc Natl Acad Sci U S A. 1991;88:10480-4.
22. Sessa WC, Harrison JK, Barber CM, Zeng D, Durieux ME, D ' Angelo DD, et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem. 1992;267:15274-8.
23. Kone BC, Kuncewicz T, Zhang W, Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol. 2003;285:F178-90.
24. Gonzales C, Barosso C, Martin C, Gulbenkian S, Estrada C. Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries. J Cereb Blood Flow Metab. 1997;17:977-84.
25. Papapetropoulos A, Desai KM, Rudic RD, Mayer B, Zhang R, Ruiz-Torres MP, et al. Nitric oxide synthase inhibitors attenuate transforming-growth-factor- beta1-stimulated capillary organization in vitro. Am J Pathol. 1997;150:1835-44.
26. Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, Vanhoutte PM. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res. 1998;83:1271-8.
27. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res. 1999;43:509-20.
28. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Proc Natl Acad Sci USA. 1993;90:347-51.
29. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995;57:2049-55.
30. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008;102:873-87.
31. Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem. 1994;63:175-95.
32. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43:521-31.
33. Groenendijk BC, Van der Heiden K, Hierck BP, Poelmann RE. The role of shear stress on ET-1, KLF2, and NOS-3 expression in the developing cardiovascular system of chicken embryos in a venous ligation model. Physiology (Bethesda). 2007;22:380-9.
34. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev. 2009;89:481-534.
35. Gimbrone MA. The Gordon Wilson lecture: Understanding vascular endothelium: a pilgrim ' s progress: endothelial dysfunction, biomechanical forces and the pathobiology of atherosclerosis. Trans Am Clin Climatol Assoc. 2010;121: 115-27.
36. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363: 15-23.
37. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res. 2007;75:247-60.
38. Oess S, Icking A, Fulton D, Govers R, M ü ller-Esterl W. Subcellular targeting and traffi cking of nitric oxide synthases. Biochem J. 2006;396:401-9.
39. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-6.
40. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor(s). Am J Physiol. 1986;250:H822-7.
41. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res. 1993;73:1121-7.
42. Lima B, Forrester MT, Hess DT, Stamler JS. Snitrosylation in cardiovascular signaling. Circ Res. 2010; 106:633-46.
43. Muller B, Kleschyov AL, Alencar JL, Vanin A, Stoclet JC. Nitric oxide transport and storage in the cardiovascular system. Ann N Y Acad Sci. 2002;962:131-9.
44. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, et al. Plasma nitrite rather than nitrate refl ects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001;98:12814-9.
45. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol. 2006;2:486-93.
46. van Faassen EE, Bahrami S, Feelisch M, Hogg N, Kelm M, Kim-Shapiro DB, et al. Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev. 2009;29:683-741.
47. Basu S, Azarova NA, Font MD, King SB, Hogg N, Gladwin MT, et al. Nitrite reductase activity of Cytochrome C. J Biol Chem. 2008;283:32590-7.
48. Gladwin MT, Kim-Shapiro DB. The functional nitrite reductase activity of the heme-globins. Blood. 2008;112: 2636-47.
49. Rapoport RM, Murad F. Agonist induced endotheliumdependent relaxation in rat thoracic aorta may be mediated though cyclic GMP. Circ Res. 1983;52:352-7.
50. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86:1-23.
51. Trepakova ES, Cohen RA, Bolotina VM. Nitric oxide inhibits capacitative cation infl ux in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2 -ATPasedependent refi lling of Ca2 stores. Circ Res. 1999;84: 201-9.
52. C ohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. Mechanism of nitric oxideinduced vasodilatation: refi lling of intracellular stores by sarcoplasmic reticulum Ca2 ATPase and inhibition of store-operated Ca2 infl ux. Circ Res. 1999;84: 210-9.
53. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Sch ö neich C, et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med. 2004;10:1200-7.
54. Tong X, Evangelista A, Cohen RA. Targeting the redox regulation of SERCA in vascular physiology and disease. Curr Opin Pharmacol. 2010;10:133-8.
55. Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:2524-31.
56. Taylor CT, Moncada S. Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia. Arterioscler Thromb Vasc Biol. 2010;30:643-7.
57. Ignarro LJ. Heme-dependent activation of guanylate cyclase by nitric oxide: a novel signal transduction mechanism. Blood Vessels. 1991;28:67-73.
58. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216-38.
59. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-91.
60. Biel M, Zong X, Ludwig A, Sautter A, Hofmann F. Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol. 1999;135:151-71.
61. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA. 1996;93: 6770-4.
62. Fö r stermann U, Mü nzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-14.
63. Chin-Dusting JP, Willems L, Kaye DM. L-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther. 2007;116:428-36.
64. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227-45.
65. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34:906-11.
66. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res. 2008;102:923-32.
67. Schulz E, Jansen T, Wenzel P, Daiber A, Mü nzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115-26.
68. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radical Res. 2003;37:121-7.
69. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006;26: 2439-44.
70. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond). 2007;113:47-63.
71. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14:753-9.
72. Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-defi cient mice. Am J Physiol Heart Circ Physiol. 2000;278:H1679-85.
73. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation. 2001;104:2391-4.
74. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase doubleknockout mice. Circulation. 2001;104:448-54.
75. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-defi cient mice. J Clin Invest. 2002;110:331-40.
76. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, H ü bschle T, et al. Antiatherosclerotic effects of smallmolecular- weight compounds enhancing endothelial nitricoxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008;325:370-9.
77. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720-6.
78. Gracia-Sancho J, Villarreal G Jr, Zhang Y, Garcí a -Cardeñ a G. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res. 2010;85:514-9.
79. Kukreja RC, Xi L. eNOS phosphorylation: a pivotal molecular switch in vasodilation and cardioprotection? J Mol Cell Cardiol. 2007;42:280-2.
80. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res. 2009;105:114-27.
81. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond). 2009;116:607-20.
82. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol. 1991; 17:964-9.
83. M ü nzel T, Gori T. Nebivolol: the somewhat-different betaadrenergic receptor blocker. J Am Coll Cardiol. 2009;54: 1491-9.
84. Vilaine JP, Biondi ML, Villeneuve N, Feletou M, Peglion JL, Vanhoutte PM. The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries. Eur J Pharmacol. 1991;197:41-8.
85. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-80.
86. Dhein S, Salameh A, Berkels R, Klaus W. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs. 1999;58:397-404.
87. Félétou M, Teisseire B. Converting enzyme inhibition in isolated porcine resistance artery potentiates bradykinin relaxation. Eur J Pharmacol. 1990;190:159-66.
88. Mombouli JV, Illiano S, Nagao T, Vanhoutte PM. The potentiation of bradykinin-induced relaxations by perindoprilat in canine coronary arteries involves both nitric oxide and endothelium-derived hyperpolarizing factor. Circ Res. 1992;71:137-44.
89. Enseleit F, Hurlimann D, Luscher TF. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol. 2001;37:S21-30.
90. Benzing T, Fleming I, Blaukat A, Mü ller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation. 1999;99:2034-40.
91. M ombouli JV, Ballard KD, Vanhoutte PM. Kininaseindependent potentiation of endothelium-dependent relaxations to kinins by converting enzyme inhibitor perindoprilat. Acta Pharmacol Sin. 2002;23:203-7.
92. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists in rats with heart failure. Role of kinins and angiotentensin II type 2 receptors. J Clin Invest. 1997;99:1926-35.
93. Katada J, Majima M. AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under fl ow conditions. Br J Pharmacol. 2002;136:484-91.
94. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat- Jeanneret L, van Kats JP, Saxena PR, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-301.
95. Li H, Wallerath T, M ü nzel T, Fö r stermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide. 2002;7: 149-64.
96. Thai H, Wollmuth J, Goldman S, Gaballa M. Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitricoxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther. 2003;307:1171-8.
97. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52:563-72.
98. Dong YF, Liu L, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia. 2010;53:180-91.
99. Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: still alive. Can J Cardiol. 2006;22:947-51.
100. Sedeek M, Hé bert RL, Kennedy CR, Burns KD, Touyz RM. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens. 2009;18:122-7.
101. Pechanova O, Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens. 2009;27 Suppl 6:S32-36.
102. Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E. Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation. Pharmacol Rep. 2009;61:105-15.
103. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313.
104. Lass è gue B, Griendling KK. Reactive oxygen species in hypertension. Am J Hypertens. 2004;17:852-60.
105. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511-5.
106. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens. 2002;20: 1671-4.
107. Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J. 2005;26:1945-55.
108. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-8.
109. Spieker LE, Flammer AJ, Lü scher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol. 2006;(176 Pt 2):249-83.
110. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles. Br J Pharmacol. 2008;155:170-84.
111. Megson IL, Webb DJ. Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs. 2002;11:587-601.
112. Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des. 2009;15:614-36.
113. Iwanaga Y, Gu Y, Dieterle T, Presotto C, Del Soldato P, Peterson KL, et al. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB J. 2004;18:587-8.
114. Okuyama CE, Mendes GD, Faro R, Rezende VM, Lagos RM, Astigarraga RE, et al. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. Clin Exp Pharmacol Physiol. 2007;34:290-5.
115. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-68.
116. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol. 2003;64:533-46.
117. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-414.
118. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995; 48:184-8.
119. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;191:277-308.
120. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S, et al. Targeting the hemeoxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116: 2552-61.
121. Schmidt HH, Schmidt PM, Stasch JP. NO- and haemindependent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;191:309-39.
122. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101:1084-95.
123. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569-78.
124. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006;147 Suppl 1:S252-7.
125. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75:303-14.
126. Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep. 2008;10:52-7.
127. Edwards G, Feletou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pfl ugers Arch. 2010;459:863-79.
128. Feletou M, K öh ler R, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep. 2010;12:267-75.
129. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pfl ugers Arch. 2010; 59:881-95.
130. Chawengsub Y, Gauthier KM, Campbell WB. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol. 2009; 297:H495-507.
131. Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Mol Cell Cardiol. 2005;39:725-32.
132. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A. 2003;100:1426-31.
133. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-72.
134. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850-3.
135. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322: 587-90.
136. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;26:1215-25.
137. Griffi th TM. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol. 2004;141:881-903.
138. Koeppen M, Feil R, Siegl D, Feil S, Hofmann F, Pohl U, et al. cGMP-dependent protein kinase mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Hypertension. 2004;44:952-5.
139. Nagao T, Illiano S, Vanhoutte PM. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats. Am J Physiol. 1992;263: H1090-4.
140. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol. 1996;28:703-11.
141. Grgic I, Kaistha BP, Hoyer J, Köhler R. Endothelial Ca 2 -activated K channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol. 2009;157: 509-26.
142. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-7.
143. Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14,15-Epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension. 2005;45:666-71.
144. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, et al. Identifi cation of a cytochrome P450 2C9- derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol. 2006; 48:508-15.
145. Lenasi H. The role of nitric oxide- and prostacyclinindependent vasodilatation in the human cutaneous microcirculation: effect of cytochrome P450 2C9 inhibition. Clin Physiol Funct Imaging. 2009;29:263-70.
146. Virdis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, et al. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. J Clin Endocrinol Metab. 2010;95:920-7.
147. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504-10.
148. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24:3770-81.
149. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol. 2007;50:225-37.
150. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol. 2009;29:54-60.
151. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, et al. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of infl ammatory pain. J Med Chem. 2010;53: 7067-75.
152. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential (TRP) C6 channels. J Cardiovasc Pharmacol. 2011;57:140-7.
153. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens. 2009;27: 322-31.
154. Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol. 2008;52:314-23.
155. Wang YX, Ulu A, Zhang LN, Hammock B. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep. 2010; 12:174-83.
156. Zhang LN, Vincelette J, Cheng Y, Mehra U, Chen D, Anandan SK, et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol. 2009;29:1265-70.
157. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009;174:2086-95.
158. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke. 2008;39:2073-8.
159. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529-37.
160. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemiareperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008;295: H2128-34.
161. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010; 334:430-8.
162. Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, Morisseau C, et al. Soluble epoxide hydrolase defi ciency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2010;30:909-14.
163. Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol. 2010;298:H795-806.
164. Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM. Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)- cyclohexyloxy]- benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol. 2010;55:67-73.
165. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and infl ammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009;297:F740-8.
166. Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU, Babelova A, et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One. 2010;5:e11979.
167. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, et al. Inhibition of soluble epoxide hydrolase enhances the anti-infl ammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol. 2010;79:880-7.
168. Gauthier KM, Chawengsub Y, Goldman DH, Conrow RE, Anjaiah S, Falck JR, et al. 11®,12(S),15(S)-trihydroxyeicosa- 5(Z),8(Z),13(E)-trienoic acid: an endothelium-derived 15-lipoxygenase metabolite that relaxes rabbit aorta. Am J Physiol Heart Circ Physiol. 2008;294:H1467-72.
169. Aggarwal NT, Chawengsub Y, Gauthier KM, Viita H, Yla-Herttuala S, Campbell WB. Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. Hypertension. 2008; 51:246-51.
170. Pearson T, Zhang J, Arya P, Warren AY, Ortori C, Fakis A, et al. Measurement of vasoactive metabolites (hydroxyeicosatetraenoic and epoxyeicosatrienoic acids) in uterine tissues of normal and compromised human pregnancy. J Hypertens. 2010;28:2429-37.
171. W öl fl e SE, Schmidt VJ, Hoyer J, Köhler R, de Wit C. Prominent role of KCa3.1 in endothelium-derived hyperpolarizing factor-type dilations and conducted responses in the microcirculation in vivo. Cardiovasc Res. 2009;82: 476-83.
172. Brä h ler S, Kaistha A, Schmidt VJ, Wolfl e SE, Busch C, Kaistha BP, et al. Genetic defi cit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 2009;119:2323-32.
173. Zygmunt PM, Hogestatt ED. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol. 1996;117:1600-6.
174. Dora KA, Gallagher NT, McNeish A, Garland CJ. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res. 2008;102: 1247-55.
175. Ledoux J, Taylor MS, Bonev AD, Hannah RM, Solodushko V, Shui B, et al. Functional architecture of inositol 1,4, 5-trisphosphate signaling in restricted spaces of myoendothelial projections. Proc Natl Acad Sci U S A. 2008; 105:9627-32.
176. Schumacher MA, Rivard AF, Bachinger HP, Adelman JP. Structure of the gating domain of a Ca2 -activated K channel complexed with Ca2 /calmodulin. Nature. 2001;410:1120-4.
177. Liedtke W, Kim C. Functionality of the TRPV subfamily of TRP ion channels: add mechano-TRP and osmo-TRP to the lexicon! Cell Mol Life Sci. 2005;62:2985-3001.
178. Sharif-Naeini R, Dedman A, Folgering JH, Duprat F, Patel A, Nilius B, et al. TRP channels and mechanosensory transduction: insights into the arterial myogenic response. Pfl ugers Arch. 2008;456:529-40.
179. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grgic I, Harteneck C, et al. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS One. 2007;2:e827.
180. Zhang DX, Gutterman DD. TRP channel activation and endothelium-dependent dilation in the systemic circulation. J Cardiovasc Pharmacol. 2011;57:133-9.
181. M ilkau M, Köhler R, de Wit C. Crucial importance of the endothelial K channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction. FASEB J. 2010;24:3572-9.
182. Köhler R, Ruth P. Endothelial dysfunction and blood pressure alterations in K -channel transgenic mice. Pfl ugers Arch. 2010;459:969-76.
183. Taylor MS, Bonev AD, Gross TP, Eckman DM, Brayden JE, Bond CT, et al. Altered expression of small-conductance Ca 2 -activated K (SK3) channels modulates arterial tone and blood pressure. Circ Res. 2003;93:124-31.
184. Feng J, Liu Y, Clements RT, Sodha NR, Khabbaz KR, Senthilnathan V, et al. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation. 2008;118:S46-51.
185. Liu Y, Sellke EW, Feng J, Clements RT, Sodha NR, Khabbaz KR, et al. Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass. Surgery. 2008;144:239-44.
186. Luksha L, Luksha N, Kublickas M, Nisell H, Kublickiene K. Diverse mechanisms of endothelium-derived hyperpolarizing factor-mediated dilatation in small myometrial arteries in normal human pregnancy and preeclampsia. Biol Reprod. 2010;83:728-35.
187. Feletou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol. 2009;156:545-62.
188. Weston AH, Porter EL, Harno E, Edwards G. Impairment of endothelial SK(Ca) channels and of downstream hyperpolarizing pathways in mesenteric arteries from spontaneously hypertensive rats. Br J Pharmacol. 2010;160: 836-43.
189. Giachini FR, Carneiro FS, Lima VV, Carneiro ZN, Dorrance A, Webb RC, et al. Upregulation of intermediate calcium-activated potassium channels counterbalance the impaired endothelium-dependent vasodilation in strokeprone spontaneously hypertensive rats. Transl Res. 2009; 154:183-93.
190. Brondum E, Kold-Petersen H, Simonsen U, Aalkjaer C. NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Br J Pharmacol. 2009;159:154-65.
191. Hasenau AL, Nielsen G, Morisseau C, Hammock BD, Wulff H, K ö hler R. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2 -activated K -channels. Acta Physiol (Oxf). 2011 Mar 1 (Epub ahead of print).
192. Köhler R, Kaistha BP, Wulff H. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets. 2010;14:143-55.
193. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, et al. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009;75:281-95.
194. Michel FS, Man GS, Man RY, Vanhoutte PM. Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat. Br J Pharmacol. 2008;155:217-26.
195. Olmos L, Mombouli JV, Illiano S, Vanhoutte PM. cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries. Am J Physiol. 1995;268:H865-70.
196. Thollon C, Fournet-Bourguignon MP, Saboureau D, Lesage L, Reure H, Vanhoutte PM, et al. Consequences of reduced production of NO on vascular reactivity of porcine coronary arteries after angioplasty: importance of EDHF. Br J Pharmacol. 2002;136:1153-61.
197. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL, Vanhoutte PM, et al. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A. 2000;97:9747-52.
198. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003; 424:434-8.
199. Dalsgaard T, Kroigaard C, Misfeldt M, Bek T, Simonsen U. Openers of small conductance calcium-activated potassium channels selectively enhance NO-mediated bradykinin vasodilatation in porcine retinal arterioles. Br J Pharmacol. 2010;160:1496-508.
200. Schmidt K, Dubrovska G, Nielsen G, Fes ü s G, Uhrenholt TR, Hansen PB, et al. Amplifi cation of EDHF-type vasodilatations in TRPC1-defi cient mice. Br J Pharmacol. 2010; 161:1722-33.
201. Sheng JZ, Ella S, Davis MJ, Hill MA, Braun AP. Openers of SKCa and IKCa channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar vasodilation. FASEB J. 2009;23:1138-45.
202. Yanagisawa M, Kurihara H, Kimura S, Tomobe TY, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-15.
203. Schini VB, Vanhoutte PM. Endothelin-1: A potent vasoactive peptide. Pharmacol Toxicol. 1991;69:1-7.
204. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev. 1994;6:325-415.
205. Nava E, Lü scher TF. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens Suppl. 1995;13:S39-48.
206. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertension. 1998;1891-5.
207. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61: 391-415.
208. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol. 2007;50:621-8.
209. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, et al. Low blood pressure in endothelial cellspecifi c endothelin 1 knockout mice. Hypertension. 2010; 56:121-8.
210. Vanhoutte PM. Is endothelin involved in the pathogenesis of hypertension? Hypertension. 1993;21:747-51.
211. Goel A, Su B, Flavahan S, Lowenstein CJ, Berkowitz DE, Flavahan NA. Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. Circ Res. 2010;107:242-51.
212. d e Andrade CR, Leite PF, Montezano AC, Casolari DA, Yogi A, Tostes RC, et al. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia. Br J Pharmacol. 2009; 157:568-80.
213. Raja SG. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther. 2010; 28:e65-71.
214. Schiffrin EL. Endothelin: role in experimental hypertension. J Cardiovasc Pharmacol. 2000;35:S33-5.
215. Boulanger C, Lü scher TF. Release of endothelium from the porcine aorta: inhibition of endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-90.
216. Lü scher TF, Boulanger CM, Yang Z, Dohi Y. Interaction between endothelin and endothelium-derived relaxing factor(s). In: Rubanyi GM, editor. Endothelin. New York, NY: Oxford University Press; 1992.
217. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol. 1994;158:485-94.
218. Miller VM, Komori K, Burnett JC Jr, Vanhoutte PM. Differential sensitivity to endothelin in canine arteries and veins. Am J Physiol. 1989;257:H1127-31.
219. Chen Y, McCarron RM, Golech S, Bembry J, Ford B, Lenz FA, et al. ET-1- and NO-mediated signal transduction pathway in human brain capillary endothelial cells. Am J Physiol Cell Physiol. 2003;284:C243-9.
220. Deuchar GA, Docherty A, MacLean MR, Hicks MN. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol. 2002; 135:1060-8.
221. Matsumoto T, Ishida K, Nakayama N, Kobayashi T, Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol. 2009;296:H1388-97.
222. Flavahan NA, Vanhoutte PM. G-proteins and endothelial responses. Blood Vessels. 1990;27:218-29.
223. Flavahan NA, Vanhoutte PM. Endothelial cell signaling and endothelial dysfunction. Am J Hypertens. 1995;8: S28-41.
224. Schini VB, Kim ND, Vanhoutte PM. The basal and stimulated release of EDRF inhibits the contractions evoked by endothelin-1 and endothelin-3 in aortae of normotensive and spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17:S266-70.
225. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension. 2006;48:286-93.
226. B agnall A, Webb D, Kotelevtsev Y. A transgenic strategy for analysis of the function of the endothelin-B-receptor. J Cardiovasc Pharmacol. 2000;36(5 Suppl 1):S90-2.
227. Tykocki NR, Gariepy CE, Watts SW. Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein. J Pharmacol Exp Ther. 2009;329:875-81.
228. Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N. Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension. 2010;56:129-35.
229. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation. 1999;100:1680-83.
230. Vanhoutte PM, Félétou M, Taddei S. Endotheliumdependent contractions in hypertension. Br J Pharmacol. 2005;144:449-58.
231. Vanhoutte PM, Tang EHC. Endothelium-dependent contractions: when a good guy turns bad! J Physiol. 2008;586.22:5295-304.
232. Félétou M, Huang Y, Vanhoutte PM. Vasoconstrictor prostanoids. Pfl ugers Arch. 2010;459:941-50.
233. Wong MSK, Vanhoutte PM. COX-mediated endotheliumdependent contractions: from the past to recent discoveries. Acta Pharmacol Sin. 2010;31:1095-102.
234. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H 2 in the SHR aorta. Circ Res. 1995;76:1003-10.
235. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Félétou M. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol. 2005;146:834-45
236. Gluais P, Paysant J, Badier-Commander C, Verbeuren T, Vanhoutte PM, Félétou M. In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A2 as endothelium-derived contracting factors. Am J Physiol Heart Circ Physiol. 2006;291:H2255-64.
237. Zhou Y, Varadharaj S, Zhao X, Parinandi N, Flavahan NA, Zweier JL. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol. 2005;289:H1027-32.
238. Leung FP, Huang Y, Félétou M, So KF, Man RY, et al. Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endotheliumderived contracting factor. Br J Pharmacol. 2007;151: 15-23.
239. Tang EHC, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther. 2009;122:140-9.
240. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension. 1990;15:699-703.
241. Félétou M, Verbeuren TJ, Vanhoutte PM. Endotheliumdependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br J Pharmacol. 2009;156:563-74.
242. Félétou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/ endoperoxide receptor (TP): the common villain. J Cardiovasc Pharmacol. 2010;55:317-32.
243. Taddei S, Vanhoutte PM. Role of endothelium in endothelin- evoked contractions in the rat aorta. Hypertension. 1993;21:9-15.
244. Mombouli JV, Vanhoutte PM. Purinergic endotheliumdependent and independent contractions in rat aorta. Hypertension. 1993;22:577-83.
245. Park S-J, Lee JL, Vanhoutte PM. Endothelin-1 releases endothelium-derived endoperoxides and thromboxane A 2 in porcine coronary arteries with regenerated endothelium. Zhongguo Yao Lixue Bao. 1999;20:872-8.
246. Desjardins F, Aubin MC, Carrier M, Perrault LP. Decrease of endothelin receptor subtype ETB and release of COXderived products contribute to endothelial dysfunction of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2005;45:499-508.
247. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 1989;257:H33-7.
248. Cosentino F, Sill JC, Katusic ZS. Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension. 1994;23:229-35.
249. Katusic ZS. Superoxide anion and endothelial regulation of arterial tone. Free Radic Biol Med. 1996;20:443-8.
250. Shi Y, Vanhoutte PM. Reactive oxygen-derived free radicals are key to the endothelial dysfunction of diabetes. J Diabetes. 2009;1:151-62.
251. Cohen RA. Does EDCF contribute to diabetic endothelial cell dysfunction? Dialog Cardiovasc Med. 2002;7:225-31.
252. Medow MS, Taneja I, Stewart JM. Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007;293:H425-32.
253. Signori LU, da Silva AM, Plentz RD, Moreno H Jr, Irigoyen MC, Schaan BD. Reversal of postprandial endothelial dysfunction by cyclooxygenase inhibition in healthy volunteers. J Cardiovasc Pharmacol. 2009;54:90-3.
254. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol. 2009; 157:527-36.
255. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension. 1992;19:442-5.
256. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Feletou M. Nitric oxide and inactivation of the endothelium-dependent contracting factors released by acetylcholine in SHR. J Cardiovasc Pharm. 2004;43:815-20.
257. Tang EH, Félétou M, Huang Y, Man RY, Vanhoutte PM. Acetylcholine and sodium nitroprusside cause long-term inhibition of EDCF-mediated contractions. Am J Physiol Heart Circ Physiol. 2005;289:H2434-40.
258. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4:33-40.